PHARMACEUTICAL 2022

XOMA Royalty Corp
Rank 67 of 471



TOP RATED 2022

RealRate

PHARMACEUTICAL 2022

XOMA Royalty Corp
Rank 67 of 471

XOMA

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 86% points.The greatest weakness of XOMA Royalty Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 6.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 396%, being 121% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	96,973
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,967
Liabilities, Non-Current	34
Other Assets	69,576
Other Compr. Net Income	0
Other Expenses	552
Other Liabilities	11,685
Other Net Income	-1,179
Other Revenues	38,160
Property and Equipment	13
Research and Development	171
Selling, General and Administrative Expense	20,460

Output Variable	Value in 1000 USD
Assets	166,562
Liabilities	24,686
Expenses	21,183
Revenues	38,160
Stockholders Equity	141,876
Net Income	15,798
Comprehensive Net Income	15,798
BaseVar	125,885
ECR before LimitedLiability	340%
Economic Capital Ratio	396%